Assembled from the company's filings and exchange data as of today. Download PDF renders this page on the server; the narrative sections arrive with the Nexa composer.
Dossier · BIOFIL CHEM & PHARMA LTD · 29 October 2026Page 1 of 3
Company Dossier
MarketPing Research · factual · no rating expressed
BIOFIL CHEM & PHARMA LTD
NSE: BIOFILCHEM · BSE: 524396
NSE: BIOFILCHEM · BSE: 524396
Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
BIOFIL CHEM & PHARMA LTD
StateQ1 FY27 filed
Last close · 28 Oct 2026₹29.23
Market cap₹0.0k cr
TTM P/E · P/B · EV/EBITDA97.4 · 2.21 · 46.0
BIOFIL CHEM & PHARMA LTD is a Pharmaceuticals & Biotechnology company listed on NSE. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
What a broker report prints here — the analyst's thesis. This dossier prints the filed record instead; the narrative read of the latest results, the guidance ledger and the earnings-call summary are the composer's sections (INSTITUTIONAL-PLAN.md M3) and are not yet produced.
Exhibit 1: Financial summary, FY22–FY26 (all audited; no estimate years)
| ₹ crore · standalone | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 22 | 30 | 40 | 33 | 28 |
| EBITDA (ex other income) | 1 | 1 | 1 | 1 | 1 |
| margin % | 6.0 | 3.9 | 2.0 | 2.5 | 2.3 |
| Owners' profit | 1 | 1 | 1 | 1 | 3 |
| EPS, as reported (₹) | 0.44 | 0.29 | 0.44 | 0.34 | 1.71 |
| ROE % · ROCE % | 4.1 · 6.1 | 3.2 · 4.7 | 3.9 · 4.9 | 3.0 · 4.0 | 12.9 · 15.6 |
| Debt / equity (x) | 0.03 | 0.03 | 0.02 | 0.03 | 0.14 |
| Cash from operations | (0) | (0) | 2 | (2) | (1) |
| Capex | (0) | (0) | (0) | (0) | (0) |
Source: SEBI results XBRL as filed with BSE/NSE; EBITDA excludes other income.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BIOFIL CHEM & PHARMA LTD · 29 October 2026Page 2 of 3
Exhibit 2: Quarterly performance, last 8 quarters
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 14 | 8 | 6 | 14 | 1 | 8 | 12 |
| Profit before tax | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.01 | 0.10 | 0.12 | 1.48 | 0.05 | 0.05 | 0.13 | 0.07 |
Source: quarterly results as filed; the balance sheet is filed half-yearly and is not repeated here.
Exhibit 3: Segment revenue, FY26
| Segment | Revenue, ₹ crore | Share % |
|---|---|---|
| Pharma Division | 6 | 21.0 |
| Chemical Division | 8 | 28.3 |
| Pharma Unit | 13 | 45.8 |
| Chemicals Division | 1 | 4.9 |
| Total, before eliminations | 28 | 100.0 |
Source: the filed segment block, four quarters summed.
Exhibit 4: Peers — basic industry group, by market cap
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| SUN PHARMACEUTICAL IND L | 4,21,677 | 34.9 | 5.03 | 22.6 | 13.7 | 17.5 | 11.8 | 32.3 |
| DIVI S LABORATORIES LTD | 2,53,976 | 87.0 | 15.15 | 65.5 | 15.3 | 18.8 | 8.7 | 42.8 |
| TORRENT PHARMACEUTICALS L | 1,54,957 | 73.1 | 8.81 | 38.5 | 12.2 | 8.0 | 11.8 | 33.1 |
| LAURUS LABS LIMITED | 1,17,877 | 107.7 | 21.70 | 65.6 | 16.4 | 17.2 | 7.2 | 32.0 |
| ZYDUS LIFESCIENCES LTD | 1,17,315 | 26.2 | 3.97 | 15.1 | 17.3 | 18.0 | 12.4 | 25.2 |
| DR. REDDY S LABORATORIES | 1,11,506 | 34.5 | 2.92 | 14.9 | 10.9 | 13.0 | 12.1 | 15.0 |
| CIPLA LTD | 1,10,320 | 32.7 | 3.20 | 16.9 | 11.2 | 14.7 | 8.0 | 19.7 |
| MANKIND PHARMA LIMITED | 1,02,829 | 50.3 | 6.21 | 28.3 | 11.7 | 10.8 | — | 27.3 |
Source: exchange data and filed statements via the screener; multiples at current prices.
Exhibit 5: Where the company sits in its group
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 97.4 | 30.8 | 140 of 158 | 12% |
| P/B | 2.2 | 3.1 | 62 of 163 | 62% |
| ROCE | 15.6 | 10.8 | 59 of 183 | 68% |
| ROE | 12.9 | 9.8 | 57 of 166 | 66% |
| Debt / Equity | 0.1 | 0.2 | 81 of 166 | 52% |
| EBITDA margin | 1.6 | 17.5 | 152 of 165 | 8% |
| Revenue growth | 92.0 | 16.3 | 11 of 161 | 94% |
| Profit growth | (95.5) | 30.9 | 145 of 158 | 8% |
| Market cap | 48 | 806 | 146 of 181 | 19% |
Source: MarketPing peer ranks; a rank is a measurement, not a view.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in
Dossier · BIOFIL CHEM & PHARMA LTD · 29 October 2026Page 3 of 3
Exhibit 6: Filings of the last 90 days, with the measured price reaction
| Date · filing | Category | Importance | Next day % | 5-day % |
|---|---|---|---|---|
| 6 Oct 2026 · Routine quarterly RTA certificate for securities dematerialization Q2 FY26 | compliance | minimal | — | — |
| 24 Sept 2026 · Trading Window Closure from Oct 1, 2026 for Q2 Results | compliance | minimal | — | — |
| 24 Sept 2026 · Shareholder nod to continue 75+ Independent Director | management changes | medium | — | — |
| 24 Sept 2026 · AGM 2026: All 4 resolutions passed including related party transaction | compliance | minimal | — | — |
| 23 Sept 2026 · Summary of 41st AGM proceedings - 23 Sept 2026 | board shareholder meetings | medium | — | — |
| 28 Aug 2026 · Newspaper ad disclosing 41st AGM notice and remote E-voting details | compliance | minimal | — | — |
| 26 Aug 2026 · E-voting details for 41st AGM on 23 September 2026 | compliance | minimal | — | — |
| 26 Aug 2026 · Intimation of letter to shareholders without registered email for 41st AGM | compliance | minimal | — | — |
| 26 Aug 2026 · Biofil Pharma files FY26 Annual Report, sets Sept 23 AGM for shareholder approvals | board shareholder meetings | low | — | — |
| 26 Aug 2026 · 41st AGM notice - September 23, 2026 via video conferencing | board shareholder meetings | low | — | — |
Source: exchange announcements; each reaction is measured from the close before the filing. Next day = the close one session after the reaction day (the first session that could trade the filing).
How to read this document
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
Sources, method and disclosures
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
Every figure is a filed number or a ratio over filed numbers · No rating, target or fair value is expressed · Disclosures on the last pagemarketping.in